# Autism Spectrum Disorder FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/autism-spectrum-disorder

> 2 upcoming FDA catalysts in autism Spectrum Disorder: ml-004 (ir)/(er) tablet (MPLT) on November 2027 (primary completion); ml-004 (ir)/(er) tablet (MPLT) on Nov 2027 to Feb 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 10, 2026 | [Ml-004 (ir)/(er) tablet primary completion](https://sec-api.dev/pdufa/ml-004-ir-er) | MPLT | Autism Spectrum Disorder | completed | "NCT05081245 (ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-10 (ACTUAL); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05081245)) |
| November 2027 | [Ml-004 (ir)/(er) tablet primary completion](https://sec-api.dev/pdufa/ml-004-ir-er) | MPLT | Autism Spectrum Disorder | scheduled | "NCT05889273 (ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05889273)) |
| Nov 2027 to Feb 2028 | [Ml-004 (ir)/(er) tablet topline data readout](https://sec-api.dev/pdufa/ml-004-ir-er) | MPLT | Autism Spectrum Disorder | scheduled | "NCT05889273 (ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05889273)) |

## Drugs

- [Ml-004 (ir)/(er) tablet](https://sec-api.dev/pdufa/ml-004-ir-er) (MPLT)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/autism-spectrum-disorder.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Autism Spectrum Disorder FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/autism-spectrum-disorder

```bibtex
@misc{secapidev_indications_autism_spectrum_disorder_20261116,
  title        = {Autism Spectrum Disorder FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/autism-spectrum-disorder}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_autism_spectrum_disorder_20261116","title":"Autism Spectrum Disorder FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/autism-spectrum-disorder","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
